Does low c peptide mean type 1 diabetes?

Low C-peptide levels can indicate type 1 diabetes but aren't definitive on their own. While type 1 diabetes typically shows very low or undetectable C-peptide, other conditions like advanced type 2 diabetes or pancreatic disorders can also cause low levels.

Questions on this topic?Ask Sai, our AI longevity expert.
Ask Sai

Understanding C-Peptide and Its Role in Diabetes Diagnosis

C-peptide is a crucial biomarker that helps healthcare providers distinguish between different types of diabetes and assess pancreatic function. When your pancreas produces insulin, it releases an equal amount of C-peptide into your bloodstream. This one-to-one relationship makes C-peptide an excellent indicator of how much insulin your body naturally produces.

Unlike insulin, which gets cleared from the blood quickly and can be affected by injected insulin, C-peptide remains in circulation longer and provides a more accurate picture of your pancreatic beta cell function. This stability makes it particularly valuable for diagnosing diabetes type and monitoring disease progression.

What Is C-Peptide?

C-peptide, short for connecting peptide, is a byproduct of insulin production. When your pancreatic beta cells create insulin, they first produce a larger molecule called proinsulin. This proinsulin then splits into two parts: active insulin and C-peptide. Both are released into your bloodstream in equal amounts, making C-peptide a reliable marker of endogenous (internally produced) insulin.

C-Peptide Levels and Clinical Interpretation

C-peptide interpretation requires consideration of glucose levels, diabetes duration, and kidney function.
C-Peptide LevelInterpretationTypical ConditionsClinical Implications
<0.2 ng/mL<0.2 ng/mLVery Low/AbsentType 1 diabetes, advanced type 2, pancreatectomyRequires insulin therapy
0.2-0.5 ng/mL0.2-0.5 ng/mLLowEarly type 1, long-standing type 2, pancreatic diseaseMay need insulin, close monitoring
0.5-2.0 ng/mL0.5-2.0 ng/mLNormal (fasting)Healthy individuals, early type 2 diabetesNormal beta cell function
>2.0 ng/mL>2.0 ng/mLHighInsulin resistance, insulinoma, kidney diseaseEvaluate for insulin resistance

C-peptide interpretation requires consideration of glucose levels, diabetes duration, and kidney function.

The normal range for C-peptide varies by laboratory but typically falls between 0.5 to 2.0 nanograms per milliliter (ng/mL) when fasting. After eating or during a glucose tolerance test, these levels can rise significantly in healthy individuals, often reaching 3-5 times the fasting level.

Why C-Peptide Testing Matters

C-peptide testing serves several important purposes in diabetes care. It helps differentiate between type 1 and type 2 diabetes, especially in cases where the diagnosis isn't clear. It can also detect insulin resistance, monitor pancreatic function over time, and guide treatment decisions. For people already diagnosed with diabetes, C-peptide levels can indicate whether their pancreas still produces some insulin, which can influence medication choices.

If you're experiencing symptoms of diabetes or have been recently diagnosed, understanding your C-peptide levels can provide valuable insights into your condition. Regular monitoring through comprehensive testing can help track changes in pancreatic function over time.

Low C-Peptide Levels and Type 1 Diabetes

Type 1 diabetes is an autoimmune condition where the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As these cells are destroyed, both insulin and C-peptide production decline dramatically. This is why people with type 1 diabetes typically have very low or undetectable C-peptide levels.

However, low C-peptide alone doesn't automatically mean type 1 diabetes. The relationship is strong but not absolute. Studies show that while most people with type 1 diabetes have C-peptide levels below 0.2 ng/mL, some may retain minimal beta cell function for years after diagnosis, a phenomenon known as the honeymoon phase.

The Autoimmune Connection

In type 1 diabetes, autoantibodies attack the pancreatic beta cells, leading to their destruction. Common autoantibodies include GAD antibodies, IA-2 antibodies, and insulin autoantibodies. The presence of these antibodies, combined with low C-peptide levels, provides strong evidence for type 1 diabetes. This is why comprehensive testing often includes both C-peptide and autoantibody panels.

The autoimmune process can begin years before symptoms appear. During this time, C-peptide levels may gradually decline as more beta cells are destroyed. Early detection through regular testing can help identify this decline before complete beta cell failure occurs.

Other Causes of Low C-Peptide

While low C-peptide is strongly associated with type 1 diabetes, several other conditions can also result in reduced C-peptide levels. Understanding these alternatives is crucial for accurate diagnosis and appropriate treatment.

Advanced Type 2 Diabetes

Long-standing type 2 diabetes can lead to beta cell exhaustion, resulting in decreased insulin and C-peptide production. This typically occurs after many years of the disease, especially in cases with poor glycemic control. Unlike type 1 diabetes, this decline is gradual and not caused by autoimmune destruction.

People with advanced type 2 diabetes may have C-peptide levels that overlap with those seen in type 1 diabetes, making differential diagnosis challenging. In these cases, autoantibody testing and clinical history become essential for determining the correct diabetes type.

Pancreatic Disorders

Various pancreatic conditions can impair insulin production and lower C-peptide levels. Chronic pancreatitis, pancreatic cancer, cystic fibrosis-related diabetes, and surgical removal of the pancreas can all result in reduced C-peptide. These conditions damage or remove the tissue containing beta cells, leading to decreased insulin production.

Hemochromatosis, a condition causing iron overload, can also damage the pancreas and reduce C-peptide levels. Similarly, certain medications, particularly those used in cancer treatment, may temporarily or permanently affect pancreatic function.

Interpreting C-Peptide Test Results

C-peptide test results must be interpreted in context with other clinical findings. A single low C-peptide reading doesn't provide a complete picture. Factors such as the duration of diabetes, current blood glucose levels, and whether the test was performed fasting or after stimulation all influence the interpretation.

Testing Methods and Timing

C-peptide can be measured through blood or urine tests. Blood tests are more common and can be performed fasting or after stimulation with glucose or glucagon. Stimulated tests often provide more information about residual beta cell function, especially in early diabetes.

The timing of C-peptide testing matters significantly. In newly diagnosed diabetes, C-peptide levels may still be detectable even in type 1 diabetes. Testing too early in the disease process might not reveal the full extent of beta cell loss. Conversely, testing years after diagnosis in someone with type 2 diabetes might show low levels due to beta cell exhaustion rather than autoimmune destruction.

Upload your blood test results to track your progress

Seamlessly upload 3rd party biomarker & blood tests to track your whole health in 1 dashboard. Understand what each blood test means and how it fits into the bigger picture of your body and health.

Get diet and lifestyle recommendations based on your blood results, health profile and health goals. You'll also receive a custom supplement recommendation for the precise nutrients your body craves.

Upload Past Blood Test Results

Click or drag file to upload

Once you upload your report, we'll extract the results for your review. Works with top labs including Quest Diagnostics, LabCorp, BioReference, EverlyWell, LetsGetChecked and hundreds of other labs.

Additional Tests for Accurate Diagnosis

When C-peptide levels are low, additional testing helps clarify the diagnosis. These complementary tests provide a more complete picture of pancreatic function and autoimmune activity.

Autoantibody Testing

Autoantibody tests are crucial for confirming type 1 diabetes. The most common antibodies tested include:

  • Glutamic acid decarboxylase (GAD) antibodies
  • Islet antigen-2 (IA-2) antibodies
  • Insulin autoantibodies (IAA)
  • Zinc transporter 8 (ZnT8) antibodies
  • Islet cell antibodies (ICA)

The presence of one or more of these antibodies, combined with low C-peptide, strongly suggests type 1 diabetes. However, about 5-10% of people with type 1 diabetes may test negative for all antibodies, a condition sometimes called idiopathic type 1 diabetes.

Glucose and HbA1c Testing

Blood glucose and HbA1c tests help assess overall glycemic control and diabetes severity. These tests, combined with C-peptide results, provide insights into how well the body manages glucose. Fasting glucose, oral glucose tolerance tests, and HbA1c measurements are standard components of diabetes diagnosis and monitoring.

For comprehensive metabolic assessment, regular monitoring of multiple biomarkers provides the most complete picture of your health status. Understanding how these markers change over time can help optimize treatment strategies.

Treatment Implications of Low C-Peptide

C-peptide levels significantly influence diabetes treatment decisions. People with very low or absent C-peptide typically require insulin therapy since their bodies cannot produce sufficient insulin naturally. Those with detectable C-peptide may have more treatment options, including oral medications that stimulate remaining beta cells.

The presence of residual C-peptide, even at low levels, offers several clinical advantages. It's associated with better glycemic control, reduced risk of hypoglycemia, and fewer diabetes complications. This is why preserving remaining beta cell function has become an important treatment goal, particularly in early type 1 diabetes.

Monitoring Beta Cell Function

Regular C-peptide monitoring helps track beta cell function over time. In type 1 diabetes, this can identify individuals who maintain some insulin production, which may influence treatment intensity. In type 2 diabetes, declining C-peptide levels might signal the need to initiate insulin therapy.

Research into beta cell preservation continues to advance. Clinical trials are investigating various approaches to protect remaining beta cells in early type 1 diabetes, including immunotherapy and combination treatments. Regular monitoring of C-peptide levels helps evaluate the effectiveness of these interventions.

Living with Low C-Peptide Levels

Managing diabetes with low C-peptide requires careful attention to blood glucose monitoring, insulin administration, and lifestyle factors. While the absence of natural insulin production presents challenges, modern diabetes management tools and techniques enable people to maintain good glycemic control and quality of life.

Key management strategies include:

  • Frequent blood glucose monitoring or continuous glucose monitoring (CGM)
  • Careful insulin dosing based on carbohydrate counting
  • Regular physical activity with appropriate adjustments
  • Stress management techniques
  • Consistent meal timing and composition
  • Regular medical follow-ups and laboratory testing

Education about recognizing and treating hypoglycemia becomes particularly important when C-peptide is absent, as the risk of low blood sugar increases without natural insulin regulation. Working with a diabetes care team helps optimize management strategies based on individual needs and circumstances.

If you're looking to better understand your metabolic health and track important biomarkers over time, consider uploading your existing lab results to SiPhox Health's free analysis service. This comprehensive tool can help you interpret your test results and provide personalized insights for managing your health.

The Bottom Line on C-Peptide and Diabetes Diagnosis

While low C-peptide levels are strongly associated with type 1 diabetes, they don't provide a definitive diagnosis on their own. The complete clinical picture, including autoantibody status, clinical presentation, and other laboratory findings, determines the correct diabetes classification. Understanding your C-peptide levels, along with other relevant biomarkers, empowers you to work effectively with your healthcare team in managing your condition.

Whether you're newly diagnosed or have been living with diabetes for years, regular monitoring of C-peptide and other metabolic markers provides valuable insights into your pancreatic function and overall health status. This information guides treatment decisions and helps optimize your diabetes management plan for the best possible outcomes.

References

  1. Jones, A. G., & Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803-817.[Link][PubMed][DOI]
  2. Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017). A practical review of C-peptide testing in diabetes. Diabetes Therapy, 8(3), 475-487.[Link][PubMed][DOI]
  3. Palmer, J. P., Fleming, G. A., Greenbaum, C. J., et al. (2004). C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function. Diabetes, 53(1), 250-264.[Link][PubMed][DOI]
  4. Shields, B. M., McDonald, T. J., Oram, R., et al. (2018). C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase. Diabetes Care, 41(7), 1486-1492.[Link][PubMed][DOI]
  5. Hope, S. V., Knight, B. A., Shields, B. M., et al. (2016). Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 59(1), 66-74.[Link][PubMed][DOI]
  6. Greenbaum, C. J., Beam, C. A., Boulware, D., et al. (2012). Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes, 61(8), 2066-2073.[Link][PubMed][DOI]

Was this article helpful?

Frequently Asked Questions

How can I test my C-peptide at home?

You can test your C-peptide at home with SiPhox Health's Heart & Metabolic Program or Ultimate 360 Health Program. Both programs include C-peptide testing along with other essential metabolic biomarkers, providing comprehensive insights into your pancreatic function and metabolic health.

What is the normal range for C-peptide?

Normal C-peptide levels typically range from 0.5 to 2.0 ng/mL when fasting. After eating or during a glucose stimulation test, levels can rise to 3-5 times the fasting value in healthy individuals. Values below 0.2 ng/mL are considered very low and may indicate significant beta cell dysfunction.

Can C-peptide levels improve over time?

In type 1 diabetes, C-peptide levels generally don't improve significantly once beta cells are destroyed. However, in type 2 diabetes, improving insulin sensitivity through weight loss, exercise, and medication can sometimes help preserve or slightly improve remaining beta cell function. Early intervention is key to maintaining C-peptide production.

How often should C-peptide be tested?

Testing frequency depends on your situation. Newly diagnosed individuals might benefit from testing every 3-6 months to track beta cell function. Those with established diabetes may test annually or when considering treatment changes. Your healthcare provider can recommend an appropriate testing schedule based on your specific needs.

What's the difference between C-peptide and insulin tests?

While both reflect insulin production, C-peptide provides a more accurate picture of natural insulin production. Insulin tests can be affected by injected insulin and clear from the blood quickly. C-peptide remains stable longer and isn't affected by insulin injections, making it ideal for assessing pancreatic function in people taking insulin.

This article is licensed under CC BY 4.0. You are free to share and adapt this material with attribution.

Ask Questions About Any Health Topic

Chat with Sai, our AI health assistant, for personalized insights.

Click or drag file to upload blood test results

Backed By Leading Experts in Health Optimization

Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Clinical Product Operations

Director of Clinical Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, contributing to patents, launching health-related products, and turning diagnostics into actionable tools.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Robert Lufkin, MD

Robert Lufkin, MD

Advisor

Physician/medical school professor (UCLA and USC) and New York Times bestselling author empowering people to take back their metabolic health with lifestyle and other tools. A veteran of the Today Show, USA Today, and a regular contributor to FOX and other network news stations, his weekly video podcast reaches over 500,000 people. After reversing chronic disease and transforming his own life he is making it his mission to help others do the same.

His latest book, ‘Lies I Taught In Medical School’ is an instant New York Times bestseller and has re-framed how we think about metabolic health and longevity. In addition to being a practicing physician, he is author of over 200 peer reviewed scientific papers and 14 books that are available in fourteen languages.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Clinical Product Operations

Director of Clinical Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, contributing to patents, launching health-related products, and turning diagnostics into actionable tools.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Robert Lufkin, MD

Robert Lufkin, MD

Advisor

Physician/medical school professor (UCLA and USC) and New York Times bestselling author empowering people to take back their metabolic health with lifestyle and other tools. A veteran of the Today Show, USA Today, and a regular contributor to FOX and other network news stations, his weekly video podcast reaches over 500,000 people. After reversing chronic disease and transforming his own life he is making it his mission to help others do the same.

His latest book, ‘Lies I Taught In Medical School’ is an instant New York Times bestseller and has re-framed how we think about metabolic health and longevity. In addition to being a practicing physician, he is author of over 200 peer reviewed scientific papers and 14 books that are available in fourteen languages.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Clinical Product Operations

Director of Clinical Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, contributing to patents, launching health-related products, and turning diagnostics into actionable tools.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Robert Lufkin, MD

Robert Lufkin, MD

Advisor

Physician/medical school professor (UCLA and USC) and New York Times bestselling author empowering people to take back their metabolic health with lifestyle and other tools. A veteran of the Today Show, USA Today, and a regular contributor to FOX and other network news stations, his weekly video podcast reaches over 500,000 people. After reversing chronic disease and transforming his own life he is making it his mission to help others do the same.

His latest book, ‘Lies I Taught In Medical School’ is an instant New York Times bestseller and has re-framed how we think about metabolic health and longevity. In addition to being a practicing physician, he is author of over 200 peer reviewed scientific papers and 14 books that are available in fourteen languages.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Clinical Product Operations

Director of Clinical Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, contributing to patents, launching health-related products, and turning diagnostics into actionable tools.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Robert Lufkin, MD

Robert Lufkin, MD

Advisor

Physician/medical school professor (UCLA and USC) and New York Times bestselling author empowering people to take back their metabolic health with lifestyle and other tools. A veteran of the Today Show, USA Today, and a regular contributor to FOX and other network news stations, his weekly video podcast reaches over 500,000 people. After reversing chronic disease and transforming his own life he is making it his mission to help others do the same.

His latest book, ‘Lies I Taught In Medical School’ is an instant New York Times bestseller and has re-framed how we think about metabolic health and longevity. In addition to being a practicing physician, he is author of over 200 peer reviewed scientific papers and 14 books that are available in fourteen languages.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Clinical Product Operations

Director of Clinical Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, contributing to patents, launching health-related products, and turning diagnostics into actionable tools.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Robert Lufkin, MD

Robert Lufkin, MD

Advisor

Physician/medical school professor (UCLA and USC) and New York Times bestselling author empowering people to take back their metabolic health with lifestyle and other tools. A veteran of the Today Show, USA Today, and a regular contributor to FOX and other network news stations, his weekly video podcast reaches over 500,000 people. After reversing chronic disease and transforming his own life he is making it his mission to help others do the same.

His latest book, ‘Lies I Taught In Medical School’ is an instant New York Times bestseller and has re-framed how we think about metabolic health and longevity. In addition to being a practicing physician, he is author of over 200 peer reviewed scientific papers and 14 books that are available in fourteen languages.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details